sciencedirect PubMed review: Implications of GLP-1 Agonists on Office-Based Sedation and General Anesthesia pubmed.ncbi.nlm.nih ASA Consensus-Based Guidance on Preoperative Management of Patients on GLP-1s pubmed.ncbi.nlm.nih Similar posts
The STEP 1 trial (Wilding et al., NEJM 2021) demonstrated an average 14.9% body weight reduction with semaglutide 2.4mg weekly over 68 weeks, compared to 2.4% with placebo a magnitude of effect that no prior anti-obesity medication had achieved
Stress Management: Practice stress-reducing techniques such as meditation, yoga, or deep breathing exercises
How Payer Friction and Patient Drop-Off Undermine Obesity GLP-1 Uptake The GLP-1 market is experiencing unprecedented demand, yet despite its clinical promise for obesity, diabetes, and other conditions, patient behavior and friction throughout the treatment journey continue to erode its commercial potential
Available In-Clinic & Mobile $279-$478 Electrolyte-rich hydration therapy that supports rapid recovery and endurance after workouts, travel, or fatigue
Altogether, these findings suggest that certain -KG competitors including DM-succinate and ITA recapitulate -KG insufficiency to inhibit the YBX1AMPK axis in human cells, reinforcing the importance of -KG as an epigenetic cofactor for energy sensing
